TABLE 4.
Antibody levels in SOTRs
| Months | Comparison | Anti-N-IgG |
Anti-S-IgG |
||||
|---|---|---|---|---|---|---|---|
| Estimated ratio (%) | 95% CI | p | Estimated ratio (%) | 95% CI | p | ||
| 1 | Age <50 vs. ≥50 | 126.4 | 33.5–477.4 | .726 | 398.9 | 69.0–2306 | .120 |
| 3 | Age <50 vs. ≥50 | 194.0 | 69.1–544.1 | .204 | 248.0 | 62.0–991.0 | .195 |
| 6 | Age <50 vs. ≥50 | 38.9 | 13.2–114.4 | .085 | 116.7 | 30.5–445.7 | .819 |
| 9 | Age <50 vs. ≥50 | 97.9 | 26.8–357.3 | .974 | 300.3 | 57.4–1570 | .189 |
| 1 | Sex female vs. male | 15.1 | 4.0–57.1 | .006 | 19.0 | 3.4–106.7 | .059 |
| 3 | Sex female vs. male | 85.7 | 33.2–221.2 | .746 | 61.0 | 16.6–223.8 | .450 |
| 6 | Sex female vs. male | 65.1 | 24.2–175.2 | .390 | 134.4 | 38.3–472.1 | .640 |
| 9 | Sex female vs. male | 121.8 | 37.0–401.5 | .742 | 130.3 | 28.2–601.8 | .731 |
| 1 | Severity score 1 vs. 2–4 | 19.2 | 5.1–71.7 | .015 | 8.9 | 1.6–50.4 | .007 |
| 3 | Severity score 1 vs. 2–4 | 17.5 | 6.4–47.4 | .001 | 9.5 | 2.5–36.8 | .001 |
| 6 | Severity score 1 vs. 2–4 | 58.6 | 21.7–157.8 | .285 | 24.2 | 6.7–87.3 | .031 |
| 9 | Severity score 1 vs. 2–4 | 38.5 | 10.6–139.8 | .144 | 13.6 | 2.8–66.7 | .015 |
| 1 | MMF/AZA 0 vs. 1 | 9.0 | 2.1–38.9 | .002 | 110.6 | 17.4–705.1 | .914 |
| 3 | MMF/AZA 0 vs. 1 | 186.4 | 55.9–621.3 | .305 | 82.6 | 16.6–410.4 | .812 |
| 6 | MMF/AZA 0 vs. 1 | 31.2 | 9.2–105.5 | .061 | 27.6 | 5.7–133.0 | .107 |
| 9 | MMF/AZA 0 vs. 1 | 262.3 | 65.9–1044 | .168 | 26.8 | 4.0–178.7 | .171 |
Note: An analysis of clinical factors predicting antibody response utilizing a mixed model for repeated measures (MMRM). Estimated ratios refer to difference in antibody levels between first and second comparison groups. COVID-19 severity score was defined according to the NIH criteria (1: mild, 2: moderate, 3: severe, and 4: critical).
Values in bold are considered statistically significant with a p value <.05.
Abbreviations: AZA, azathioprine; MMF, mycophenolate mofetil.